Altimmune, Inc. Elects Mitchel Sayare as Chairman of Board of Directors
January 03, 2018 at 08:00 am
Share
Altimmune, Inc. announced the election of Mitchel Sayare as the Chairman of the company’s Board of Directors, effective January 1, 2018. The Board’s current Chairman, David Drutz, M.D., will remain on as Chairman of the Compensation Committee and Member of the Board. Mitchel Sayare joined PharmAthene’s Board of Directors in April 2010, after having served as Chairman and Chief Executive Officer of ImmunoGen engaged in the research and development of antibody-based cancer therapeutics.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
ALTIMMUNE, INC. 
